



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 49/00, 51/12	A1	(11) International Publication Number: WO 95/19184									
		(43) International Publication Date: 20 July 1995 (20.07.95)									
<p>(21) International Application Number: PCT/US95/00519</p> <p>(22) International Filing Date: 13 January 1995 (13.01.95)</p> <p>(30) Priority Data:</p> <table border="0"> <tr> <td>182,216</td> <td>14 January 1994 (14.01.94)</td> <td>US</td> </tr> <tr> <td>214,860</td> <td>18 March 1994 (18.03.94)</td> <td>US</td> </tr> <tr> <td>292,522</td> <td>18 August 1994 (18.08.94)</td> <td>US</td> </tr> </table> <p>(71) Applicants: MASSACHUSETTS INSTITUTE OF TECHNOLOGY [US/US]; 77 Massachusetts Avenue, Cambridge, MA 02139 (US). THE PENN STATE RESEARCH FOUNDATION [US/US]; 114 Kern Graduate Building, University Park, PA 16802 (US).</p> <p>(72) Inventors: COHEN, Smadar; 12 Tfuzoth Israel, 49581 Petach-Tickva (IL). ANDRIANOV, Alexander, K.; 108 Pine Street, Belmont, MA 02178 (US). WHEATLEY, Margaret; 7 Camby Chase, Media, PA 19063 (US). ALLCOCK, Harry, R.; 434 Kemmerer Road, State College, PA 16801 (US). LANGER, Robert, S.; 77 Lombard Street, Newton, MA 02158 (US).</p> <p>(74) Agent: PABST, Patrea, L.; Arnall Golden & Gregory, 2800 One Atlantic Center, 1201 West Peachtree Street, Atlanta, GA 30309-3400 (US).</p>		182,216	14 January 1994 (14.01.94)	US	214,860	18 March 1994 (18.03.94)	US	292,522	18 August 1994 (18.08.94)	US	<p>(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published</p> <p><i>With international search report.</i></p> <p><i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
182,216	14 January 1994 (14.01.94)	US									
214,860	18 March 1994 (18.03.94)	US									
292,522	18 August 1994 (18.08.94)	US									
(54) Title: POLYMERIC MICROPARTICLES CONTAINING AGENTS FOR IMAGING											
(57) Abstract											
<p>Compositions, methods for preparing and methods of using contrast agent-filled polymeric microparticles for imaging are disclosed. In a preferred embodiment, air-encapsulating microparticles are formed by ionotropically gelling synthetic polyelectrolytes such as poly(carboxylatophenoxy)phosphazene, poly(acrylic acid), poly(methacrylic acid) and methacrylic acid copolymers (Budragit's) by contact with multivalent ions such as calcium ions. In the preferred embodiment, the average size of the microparticles is less than seven μm so that they are suitable for injection intravenously. The polymeric microparticles are stable to imaging and display high echogenicity, both <i>in vitro</i> and <i>in vivo</i>. Due to their <i>in vivo</i> stability, their potential application is extended beyond vascular imaging to liver and renal diseases, fallopian tube diseases, detecting and characterizing tumor masses and tissues, and measuring peripheral blood velocity. The microparticles can optionally be linked with ligands that minimize tissue adhesion or that target the microparticles to specific regions.</p>											

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

POLYMERIC MICROPARTICLES CONTAINING
AGENTS FOR IMAGING

Background of the Invention

This invention is in the area of polymeric
5 delivery systems, and in particular is polymeric
microparticles that encapsulate imaging agents and
methods for their preparation and use.

Diagnostic ultrasound is a powerful, non-
invasive tool that can be used to obtain
10 information on the internal organs of the body.
The advent of grey scale imaging and color Doppler
have greatly advanced the scope and resolution of
the technique. Although techniques for carrying
out diagnostic ultrasound have improved
15 significantly, there is still a need to enhance the
resolution of the imaging for: (i) cardiac, solid
organ, and vascular anatomic conduits (for example,
the imaging of macrophage activity); (ii) solid
organ perfusion; and (iii) Doppler signals of blood
20 velocity and flow direction during real-time
imaging.

Traditional, simple ultrasonic echograms
reveal blood vessel walls and other echo-producing
structures. However, since echoes from blood
25 normally are not recorded, identifying which echoes
are from which blood vessels is usually difficult.
For example, echoes from the far wall of one blood
vessel can be confused with the near wall of an
adjacent blood vessel, and vice versa.

30 Ultrasonic contrast agents can be used to
increase the amount of ultrasound reflected back to
a detector. Ultrasonic contrast mediums fill the
entire intraluminal space with echoes and readily
permit identification of the correct pair of echoes
35 corresponding to the walls of a particular blood
vessel.

Ultrasonic contrast agents are primarily used in high-flow systems in which the contrast enhancement can be quickly evanescent. For echocardiography, a full display of bubble agents, ranging in size from two μm to 12 μm , and persisting from two or three to 30 seconds, has been used. For other applications, such as neurosonography, hysterosalpingography, and diagnostic procedures on solid organs, the agent must have a lifetime of more than a few circulation times and concentrate in organ systems other than the vascular tree into which it is injected. It must also be small enough to pass through the pulmonary capillary bed (less than eight microns).

Aqueous suspensions of air microbubbles are the preferred echo contrast agents due to the large differences in acoustic impedance between air and the surrounding aqueous medium. After injection into the blood stream, the air bubbles should survive at least for the duration of examination. The bubbles should be injectable intravenously and small enough to pass through the capillaries of the lungs.

The simplest suspension of air bubbles has been obtained by hand agitation of 70% dextrose or sorbitol solutions. However, this method produces large bubbles with an average diameter of greater than 15 μm that exhibit a very limited *in vitro* stability (less than 1 minute). Feinstein, S.B., et al., J. Am. Coll. Cardiol., Vol. 3, pp. 14-20 (1984); Keller, M.W., et al., J. Ultrasound Med., Vol. 5, pp. 493-498 (1986). Smaller bubbles (usually approximately five μm in diameter) have been obtained by sonicating solutions of 50% or 70% dextrose or Renografin-76 (diatrizoate meglumin 66%) but their *in vitro* persistence still seldom exceeds a few minutes (Feinstein, J. Am. Coll.

Cardiol. 11, 59-65 (1988), and Keller, (1988)), and their *in vivo* persistence only a few seconds. This short lifetime may be appropriate for some applications in cardiology but may not be sufficient for organ imaging.

Air-filled particles with a polymeric shell should exhibit a longer persistence after injection than a nonpolymeric microbubble, and may be suitable not only for cardiology but also for organ and peripheral vein imaging. A variety of natural and synthetic polymers have been used to encapsulate imaging contrast agents, such as air. Research efforts in this area have to date primarily focused on agarose, proteins such as albumin and gelatin, and alginate as the encapsulating polymers.

Agarose gel microbeads can be formed by emulsifying agarose-parafilm oil mixtures or through the use of teflon molds. In both cases, temperature-mediated gelation of agarose requires temperature elevations that render difficult the encapsulation gaseous imaging contrast agents.

Alginate, on the other hand, can be ionically cross-linked with divalent cations, in water, at room temperature, to form a hydrogel matrix, as described by Wheatley, et al., Biomaterials 11, 713-718 (1990) and Kwok, K.K., et al., Pharm. Res., Vol. 8(3) pp. 341-344 (1991). Wheatley, et al., produced small ionically crosslinked microcapsules, which were formed of alginate, encapsulating air, for use in diagnostic ultrasound. Kwok produced microparticles in the range of 5 to 15 μm by spraying a sodium alginate solution from an air-atomizing device into a calcium chloride solution to effect crosslinking, and then further crosslinking the resulting microcapsules with poly-L-lysine.

Schneider, et al., Invest. Radiol., Vol. 27, pp. 134-139 (1992) described three micron, air-filled polymeric particles. These particles were stable in plasma and under applied pressure.

5 However, at 2.5 MHz, their echogenicity was low. Another drawback of these particles was that organic solvents (tetrahydrofuran and cyclohexane) were used to prepare the particles. Organic solvents can be difficult to remove from the

10 microbubble and may cause a health risk to the patient.

Another type of microbubble suspension has been obtained from sonicated albumin. Feinstein, et al., J. Am. Coll. Cardiol., Vol. 11, pp. 59-65

15 (1988). Feinstein describes the preparation of microbubbles that are appropriately sized for transpulmonary passage with excellent stability in vitro. However, these microbubbles are short-lived in vivo ($T_{1/2}$ = few seconds, which is approximately

20 equal to one circulation pass) because of their instability under pressure (Gottlieb, S., et al., J. Am. Soc. Echo, Vol. 3, pp. 328 (1990), Abstract; Shapiro, J.R., et al., J. Am. Coll. Cardiol., Vol. 16, pp. 1603-1607 (1990)).

25 Gelatin-encapsulated air bubbles have been described by Carroll, et al. (Carroll, B.A., et al., Invest. Radiol., Vol. 15, pp. 260-266 (1980); and Carroll, B.A., et al., Radiology, Vol. 143, pp. 747-750 (1982)), but due to their large sizes (12

30 and 80 μ m) they would likely not pass through pulmonary capillaries. Gelatin-encapsulated microbubbles have also been described in PCT/US80/00502 by Rasor Associates, Inc. These are formed by "coalescing" the gelatin.

35 Microbubbles stabilized by microcrystals of galactose (SHU 454 and SHU 508) have also been reported by Fritzsche, T., et al., Invest. Radiol.

Vol. 23 (Suppl 1), pp. 302-305 (1988); Fritzsche, T., et al., Invest. Radiol., Vol. 25 (Suppl 1), 160-161 (1990). The microbubbles last up to 15 minutes *in vitro* but less than 20 seconds *in vivo*
5 (Rovai, D., et al., J. Am. Coll. Cardiol., Vol. 10, pp. 125-134 (1987); Smith, M., et al., J. Am. Coll. Cardiol., Vol. 13, pp. 1622-1628 (1989).

A disadvantage of using natural polymers is that their biocompatibility is variable, and, due
10 to impurities in the preparation extracts, it is difficult to reproduce some properties of the polymer. Synthetic polymers are preferable because they are reproducible and their properties can be tailored to specific needs, including
15 biodegradability.

Synthetic polymers are used increasingly in medical science since they can incorporate specific properties such as strength, hydrogel
characteristics, permeability and biocompatibility,
20 particularly in fields like cell encapsulation and drug delivery, where such properties are often prerequisites. However, typical methods for the fabrication of synthetic polymers into matrices or drug delivery particles involve heat, which makes
25 encapsulating gaseous imaging contrast agents particularly difficult, or organic solvents, which may be injurious to the health of the patient.

European Patent Application No. 91810366.4 by Sintetica S.A. (0 458 745 A1) discloses air or
30 gas microballoons bounded by an interfacially deposited polymer membrane that can be dispersed in an aqueous carrier for injection into a host animal or for oral, rectal, or urethral administration, for therapeutic or diagnostic purposes. The
35 microballoons are prepared by the steps of: emulsifying a hydrophobic organic phase into a water phase to obtain an oil-in-water emulsion;

adding to the emulsion at least one polymer in a volatile organic solvent that is insoluble in the water phase; evaporating the volatile solvent so that the polymer deposits by interfacial precipitation around the hydrophobic phase in the water suspension; and subjecting the suspension to reduced pressure to remove the hydrophobic phase and the water phase in a manner that replaces air or gas with the hydrophobic phase. There are two major disadvantages of this process. First, only polymers that have very specific solubility profiles can be used to prepare the microbubbles, i.e., they must be "interfacially depositable" on a hydrophobic phase in an aqueous medium, and soluble in a volatile organic solvent that is water-insoluble. Second, the process requires the use of organic solvents, which may be hard to completely remove from the microbubble and which may be injurious to the patient's health.

It would be useful to have a method to encapsulate imaging contrast agents with biodegradable or nonbiodegradable synthetic polymers that can be accomplished without the use of elevated temperatures or organic solvents.

Another disadvantage of current microbubble technology is the tendency of the microbubble to adhere to tissues, and the inability to effectively target the microbubbles to specific regions of interest in the body, for example, a solid tumor site or disperse tumor cells. It would be desirable to have a polymeric microbubble that has a surface that minimizes tissue adhesion, or that can be designed to target to specific regions in the body.

It is therefore an object of the present invention to provide microparticles made from synthetic polymers containing an imaging agent.

It is another object of the present invention to provide microparticles containing an imaging agent that can persist for more than a few circulation times.

5 It is still another object of the present invention to provide microparticles containing imaging agents that can be prepared without the use of heat or organic solvents.

10 It is a further object of the present invention to provide methods for preparing these microparticles containing imaging agents.

It is still a further object of the present invention to provide microparticles containing imaging agents that do not adhere to tissues.

15 It is yet a further object of the invention to provide microparticles containing imaging agents that are targeted to specific regions of the body.

Summary of the Invention

20 Ionically crosslinked synthetic polymeric microparticles or synthetic polymeric microsponges containing imaging agents, and methods for their preparation and use, are disclosed. The polymeric microparticles are useful in diagnostic ultrasound imaging, magnetic resonance imaging (MRI),
25 fluoroscopy, x-ray, and computerized tomography, and can be prepared in micron and submicron sizes that are injectable and that are capable of passing through the pulmonary capillary bed.

30 The microparticles are prepared by crosslinking a water-soluble synthetic polymer that contains charged side chains with multivalent ions of the opposite charge. The product, typically a hydrogel, is optionally further stabilized by exposing the product to multivalent polyions,
35 preferably in the form of an ionic polymer, of the same charge as those used to form the hydrogel.

In the preferred embodiment, hydrolytically stable poly(organophosphazenes) such as poly(carboxylatophenoxy)phosphazene and its copolymers, poly(acrylic acid), poly(methacrylic acid) or methacrylic acid copolymers, that contain
5 carboxylic acid, sulfonic acid or hydroxyl substituent groups, are crosslinked with divalent or trivalent pharmaceutically acceptable cations such as zinc, calcium, bismuth, barium, magnesium,
10 aluminum, copper, cobalt, nickel, chromium, or cadmium, most preferably zinc.

The microparticles can be targeted to specific regions of the body by covalently binding to the polymer a targeting molecule. The targeting
15 molecule can be, for example, a protein or peptide (such as a hormone, antibody or antibody fragment such as the Fab or Fab₂, antibody fragments, or a specific cell surface receptor ligand), lipid, polysaccharide, nucleic acid, carbohydrate, a
20 combination thereof, or other molecule, including a synthetic molecule, that identifies and localizes at the target material.

The microparticles can also be designed to minimize tissue adhesion by covalently binding a
25 poly(alkylene glycol) moiety to the surface of the microparticle. The surface poly(alkylene glycol) moieties have a high affinity for water that reduces protein adsorption onto the surface of the particle. The recognition and uptake of the
30 microparticle by the reticulo-endothelial system (RES) is therefore reduced.

In one embodiment, the terminal hydroxyl group of the poly(alkylene glycol) can be used to covalently attach biologically active molecules, or
35 molecules affecting the charge, lipophilicity or hydrophilicity of the particle, onto the surface of the microparticle. The biologically active

molecule can be a protein, carbohydrate or polysaccharide, nucleic acid, lipid, a combination thereof, or a synthetic molecule, including organic and inorganic materials.

5 In a preferred embodiment, the microparticles are prepared by sonicating solutions of synthetic polymer, typically using ultrasonic frequencies of between 5,000 and 30,000 Hz, to produce a highly aerated gassed solution, and
10 spraying the polymer solution into a solution of multivalent ions. Microparticles produced by this method are typically smaller than seven microns. In a preferred embodiment, the microparticles have a diameter in the range of between approximately
15 one and seven microns.

Detailed Description of the Invention

Synthetic polymers with ionically crosslinkable groups are crosslinked in solutions of ions of the opposite charge containing imaging
20 agents to encapsulate the imaging contrast agents. The resulting product is a population of hydrogel microparticles containing one or more imaging agents. As used herein, a "microparticle" refers to a hydrogel particle having one or more imaging
25 agents entrapped therein. These microparticles can be in the form of a "microsponge", defined herein as a polymeric matrix having voids and irregularly shaped channels dispersed therein. In one embodiment, the outer layer is crosslinked with a
30 multivalent polyion and the core material is a liquid of the same or different material as the hydrogel.

Ionic crosslinking occurs in solutions of anionic polyelectrolytes and cations, or cationic
35 polyelectrolytes and anions, due to strong electrostatic forces surrounding the polymeric chains. The formation and properties of polymers

crosslinked via polyvalent ions depend on the properties, concentrations, and distribution of the ions and the polymer. Polymer chains crosslink via cations or anions by forming complexes liganded with more than one polymer group, creating intramolecular and/or intermolecular crosslinks (C. Allain and L. Salome, Macromolecules, Vol. 23, pp. 981-987 (1990)).

In one embodiment, sterilized air is encapsulated within hydrogel microparticles. These can be subsequently further crosslinked with charged polymers to form an outer permeable membrane and can be converted into microcapsules by liquefying the core hydrogel.

Other embodiments encapsulate imaging agents useful in x-ray imaging, fluoroscopy, magnetic resonance imaging, and computerized tomography.

An important element of the method and the resulting microparticulates is that the method uses water soluble, synthetic polymers. The method for making the microparticles therefore does not require the use of non-water-miscible organic solvents, is highly reproducible and requires few processing steps. Synthetic polymers are selected that are biocompatible, and are at least partially soluble in aqueous solutions, or which form a dispersion in an aqueous solution. In a preferred embodiment, the synthetic polymer is biodegradable over a period of time, usually a few days to a few months. The rate of hydrolysis of the polymer can typically be manipulated so that it can be processed and remain intact for a desired period of time.

In a preferred embodiment, microparticles exhibit an *in vivo* lifetime of from approximately thirty seconds to thirty minutes or more, or at

least enough time to be delivered to the region of interest and for the imaging operator to carry out the diagnostic tests.

I. **Selection, Synthesis, Crosslinking, and Modification of Water-soluble Polyelectrolyte Polymers.**

A number of polymers can be used to form the cross-linked hydrogel. In general, polymers that are suitable are those that have charged side groups and are at least partially soluble in aqueous solutions, such as water, buffered salt solutions, or aqueous alcohol solutions, or a monovalent ionic salt thereof. As used herein, "partially soluble" refers to a polymer that is soluble to the extent of at least 0.001 percent by weight of aqueous solution, and preferably, soluble to an extent of at least 0.01 percent by weight.

Examples of polymers with acidic side groups that can be reacted with cations include those with carboxylic acid, sulfonic acid, sulfamic acid, phosphoric acid, phosphonic acid, hydroxyl or thiol groups with acidic hydrogens (for example, halogenated, preferably fluorinated, alcohols), boric acid, or any other moiety that will react with a cation to form a conjugate base. Examples include poly(organophosphazenes) with acidic substituent groups, poly(acrylic acids), poly(methacrylic acids), copolymers of acrylic acid and methacrylic acid, copolymers of vinyl acetate with acidic monomers, sulfonated polymers, such as sulfonated polystyrene, and copolymers formed by reacting acrylic or methacrylic acid and vinyl ether monomers or polymers.

Examples of polymers with basic side groups that can be reacted with anions include those that have amino, imino, mono- or di-(alkyl or aryl)amino, heterocyclic nitrogen, or quaternary amino groups, and specifically include poly(vinyl

amines), poly(vinyl pyridine), poly(vinyl imidazole), poly(vinyl pyrrolidone) and some amino or substituted polyphosphazenes. The ammonium quaternary salt of the polymers can also be formed
5 from the backbone nitrogens or pendant imino groups.

A. Synthesis and Selection of Polymers.

1. Polyphosphazenes.

Polyphosphazenes are polymers with
10 backbones consisting of alternating phosphorus and nitrogen, separated by alternating single and double bonds. Each phosphorous atom is covalently bonded to two pendant groups ("R"). The substituent ("R") can be any of a wide variety of
15 moieties that can vary within the polymer, including but not limited to aliphatic, aryl, aralkyl, alkaryl, carboxylic acid, heteroaromatic, carbohydrates, including glucose, heteroalkyl, halogen, (aliphatic)amino- including alkylamino-,
20 heteroaralkyl, di(aliphatic)amino- including dialkylamino-, arylamino-, diarylamino-, alkylaryl amino-, -oxyaryl including but not limited to -oxyphenylCO₂H, -oxyphenylSO₃H, -oxyphenylhydroxyl and -oxyphenylPO₃H; -oxyaliphatic
25 including -oxyalkyl, -oxy(aliphatic)CO₂H, -oxy(aliphatic)SO₃H, -oxy(aliphatic)PO₃H, and -oxy(aliphatic)hydroxyl, including -oxy(alkyl)hydroxyl; -oxyalkaryl, -oxyaralkyl, -thioaryl, -thioaliphatic including -thioalkyl, -thioalkaryl, -thioaralkyl, -NHC(O)O-(aryl or aliphatic), -O-[(CH₂)_xO]_y-CH₂)_xNH₂,
30 -O-[(CH₂)_xO]_yCH₂)_xNH(CH₂)_xSO₃H, and -O-[(CH₂)_xO]_y-(aryl or aliphatic), wherein x is 1-8 and y is an integer of 1 to 20. The groups can be
35 bonded to the phosphorous atom through, for example, an oxygen, sulfur, nitrogen, or carbon atom. The polymers can be designed to be

hydrophobic, amphophilic, or hydrophilic; water-stable or water-erodible; crystalline or amorphous; or bioinert or bioactive.

The term amino acid, as used herein, refers to both natural and synthetic amino acids, and includes, but is not limited to alanyl, valinyl, leucinyl, isoleucinyl, prolinyl, phenylalaninyl, tryptophanyl, methioninyl, glycynyl, serinyl, threoninyl, cysteinyl, tyrosinyl, asparaginyl, glutaminyl, aspartoyl, glutaoyl, lysinyl, argininyl, and histidinyl.

The term amino acid ester refers to the aliphatic, aryl or heteroaromatic carboxylic acid ester of a natural or synthetic amino acid.

The term alkyl, as used herein, refers to a saturated straight, branched, or cyclic hydrocarbon, or a combination thereof, typically of C_1 to C_{20} , and specifically includes methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, cyclopentyl, isopentyl, neopentyl, hexyl, isohexyl, cyclohexyl, 3-methylpentyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, heptyl, octyl, nonyl, and decyl.

The term (alkyl or dialkyl)amino refers to an amino group that has one or two alkyl substituents, respectively.

The terms alkenyl and alkynyl, as used herein, refers to a C_2 to C_{20} straight or branched hydrocarbon with at least one double or triple bond, respectively.

The term aryl, as used herein, refers to phenyl or substituted phenyl, wherein the substituent is halo, alkyl, alkoxy, alkylthio, haloalkyl, hydroxyalkyl, alkoxyalkyl, methylenedioxy, cyano, $C(O)$ (lower alkyl), $-CO_2H$, $-SO_3H$, $-PO_3H$, $-CO_2alkyl$, amide, amino, alkylamino and

dialkylamino, and wherein the aryl group can have up to three substituents.

The term aliphatic refers to hydrocarbon, typically of C₁ to C₂₀, that can contain one or a
5 combination of alkyl, alkenyl, or alkynyl moieties, and which can be straight, branched, or cyclic, or a combination thereof.

The term halo, as used herein, includes fluoro, chloro, bromo, and iodo.

10 The term aralkyl refers to an aryl group with an alkyl substituent.

The term alkaryl refers to an alkyl group that has an aryl substituent, including benzyl, substituted benzyl, phenethyl or substituted
15 phenethyl, wherein the substituents are as defined above for aryl groups.

The term heteroaryl or heteroaromatic, as used herein, refers to an aromatic moiety that includes at least one sulfur, oxygen, or nitrogen
20 in the aromatic ring, and that can be optionally substituted as described above for aryl groups. Nonlimiting examples are furyl, pyridyl, pyrimidyl, thienyl, isothiazolyl, imidazolyl, tetrazolyl, pyrazinyl, benzofuranyl, benzothiophenyl, quinolyl,
25 isoquinolyl, benzothienyl, isobenzofuryl, pyrazolyl, indolyl, isoindolyl, benzimidazolyl, purinyl, carbozolyl, oxazolyl, thiazolyl, isothiazolyl, 1,2,4-thiadiazolyl, isooxazolyl, pyrrolyl, pyrazolyl, quinazolinyl, pyridazinyl,
30 pyrazinyl, cinnolinyl, phthalazinyl, quinoxalinyl, xanthinyl, hypoxanthinyl, pteridinyl, 5-azacytidinyl, 5-azauracilyl, triazolopyridinyl, imidazolopyridinyl, pyrrolopyrimidinyl, and pyrazolopyrimidinyl.

35 The term heteroalkyl, as used herein, refers to a alkyl group that includes a heteroatom such as oxygen, sulfur, or nitrogen (with valence

completed by hydrogen or oxygen) in the carbon chain or terminating the carbon chain.

In one embodiment, the poly(organophosphazene) contains (i) ionized or ionizable pendant groups, and (ii) pendant groups that are susceptible to hydrolysis under the conditions of use, to impart biodegradability to the polymer. Suitable hydrolyzable groups include, for example, chlorine, amino acid, amino acid ester, imidazole, glycerol, and glucosyl.

The degree of hydrolytic degradability of the polymer will be a function of the percentage of pendant groups susceptible to hydrolysis and the rate of hydrolysis of the hydrolyzable groups. The hydrolyzable groups are believed to be replaced by hydroxyl groups in aqueous environments to provide P-OH bonds that impart hydrolytic instability to the polymer.

While the acidic or basic groups are usually on nonhydrolyzable pendant groups, they can alternatively, or in combination, also be positioned on hydrolyzable groups.

In a typical embodiment, a portion, generally 10% or less, of the side chain groups (the R groups in formula 1), are susceptible to hydrolysis.

Specific examples of hydrolyzable side chains are unsubstituted and substituted imidazoles and amino acid esters in which the group is bonded to the phosphorous atom through an amino linkage (polyphosphazene polymers in which both R groups are attached in this manner are known as polyaminophosphazenes).

In polyimidazolephosphazenes, some of the "R" groups on the polyphosphazene backbone are imidazole rings, attached to phosphorous in the backbone through a ring nitrogen atom. Other "R"

groups can be organic residues that do not participate in hydrolysis, such as methyl phenoxy groups or other groups shown in Allcock, at al., Macromolecule 10:824-830 (1977), hereby

5 incorporated by reference.

Specific examples of R groups that are not capable of hydrolysis are alkyl, aralkyl, or aryl group having 20 carbon atoms or less (more preferably 12 carbon atoms or less); or a
10 heteroalkyl or heteroaryl group having 20 or less carbons and heteroatoms (more preferably 12 or less carbon or heteroatoms). If the alkyl chain is too long, the polymer will be totally insoluble in water. The groups can be bonded to the phosphorous
15 atom through e.g., an oxygen, sulfur, nitrogen, or carbon atom.

In general, when the polyphosphazene has more than one type of pendant group, the groups will vary randomly throughout the polymer, and the
20 polyphosphazene is thus a random copolymer. Phosphorous can be bound to two like groups, or two different groups. Polyphosphazenes with two or more types of pendant groups can be produced by reacting poly(dichlorophosphazene) with the desired
25 nucleophile or nucleophiles in a desired ratio. The resulting ratio of pendant groups in the polyphosphazene will be determined by a number of factors, including the ratio of starting materials used to produce the polymer, the temperature at
30 which the nucleophilic substitution reaction is carried out, and the solvent system used. While it is very difficult to determine the exact substitution pattern of the groups in the resulting polymer, the ratio of groups in the polymer can be
35 easily determined by one skilled in the art.

It should be understood that certain groups, such as heteroaromatic groups other than

imidazole, hydrolyze at an extremely slow rate under neutral aqueous conditions, such as that found in the blood, and therefore are typically considered nonhydrolyzable groups for purposes
5 herein. However, under certain conditions, for example, low pH, as found, for example, in the stomach, the rate of hydrolysis of normally nonhydrolyzable groups (such as heteroaromatics other than imidazole) can increase to the point
10 that the biodegradation properties of the polymer can be affected. One of ordinary skill in the art using well known techniques can easily determine whether pendant groups hydrolyze at a significant rate under the conditions of use. One of ordinary
15 skill in the art can also determine the rate of hydrolysis of the polyphosphazenes of diverse structures as described herein, and will be able to select the polyphosphazene that provides the desired biodegradation profile for the targeted
20 use.

The term biodegradable polymer refers to a polymer that degrades within a period that is acceptable in the desired application, less than weeks or months, when exposed to a physiological
25 solution of pH between 6 and 8 having a temperature of between about 25°C and 37°C.

Polyphosphazenes can be made by displacing the chlorines in poly(dichlorophosphazene) with a selected substituent group or groups. Desired
30 proportions of hydrolyzable to nonhydrolyzable side chains in the polymer can be achieved by adjusting the quantity of the corresponding nucleophiles that are reacted with poly(dichlorophosphazene). The preferred polyphosphazenes have a molecular weight
35 of over 1,000.

Methods for synthesis of polyphosphazenes are described by Allcock, H.R.; et al., Inorg.

Chem. 11, 2584 (1972); Allcock, et al.,
Macromolecules 16, 715 (1983); Allcock, et al.,
Macromolecules 19, 1508 (1986); Allcock, H.R.;
Gebura, M.; Kwon, S.; Neenan, T.X. Biomaterials,
5 19, 500 (1988); Allcock, et al., Macromolecules 21,
1980 (1988); Allcock, et al., Inorg. Chem. 21(2),
515-521 (1982); Allcock, et al., Macromolecules 22,
75 (1989); U.S. Patent Nos. 4,440,921, 4,495,174
and 4,880,622 to Allcock, et al.; U.S. Patent No.
10 4,946,938 to Magill, et al., and Grolleman, et al.,
J. Controlled Release 3, 143 (1986), the teachings
of which are specifically incorporated herein. The
synthesis of ionically crosslinkable
poly(carboxylatophenoxy)phosphazene, and the
15 preparation of hydrogels from this polymer, is
taught in U.S. Patent No. 5,053,451. Other patents
on poly(organophosphazenes) include U.S. Patent Nos.
4,440,921, 4,880,622, 3,893,980, 4,990,336,
4,975,280, 5,104,947, and 4,592,755.

20 Most preferably, the polyphosphazene is a
high molecular weight, water-soluble anionic
polyphosphazene, in which a majority of side groups
in phosphazene polyelectrolytes are ionic.
Carboxylic acid groups are an example of preferred
25 ionic groups. One example of a preferred
polyanionic phosphazene is poly(carboxylato-
phenoxy)phosphazene (PCPP).

**2. Other water soluble polymers with
charged side groups.**

30 A wide variety of water soluble or
dispersible polymers with ionic side groups are
known or can be easily designed by one of ordinary
skill in the art of polymer synthesis. The
polymers are in general those that are
35 biocompatible, optionally biodegradable, and have
acidic or basic substituent groups as described in
detail above. The polymers can include nonionic
monomers that impart desired properties to the


polymer. The polymer can be a condensation polymer or addition polymer. Nonlimiting examples of monomers that can be included in condensation polymers are hydroxyacids such as lactic acid, glycolic acid, and hydroxybutyric acid, and dicarboxylic acids. Examples of useful polymers includes poly(acrylic acid) (PAA); poly(methacrylic acid) (PMA); and methacrylic acid copolymers such as Eudragit L100 and S100. Biodegradable polymers include those that degrade enzymatically and those that degrade hydrolytically.

Methods for synthesizing the other polymers described above are known to those skilled in the art. See, for example Concise Encyclopedia of Polymer Science and Polymeric Amines and Ammonium Salts, E. Goethals, editor (Pergamen Press, Elmsford, NY 1980). Many, such as poly(acrylic acid), are commercially available.

One preferred polymer is poly(meth)acrylic acid (wherein the term (meth)acrylic refers to either polymethacrylic acid or polyacrylic acid) or a copolymer of methacrylic acid or acrylic acid with another unsaturated monomer that can be ionic or nonionic. Pharmaceutical applications of poly(meth)acrylic acids are well known [K.O.R. Lehman in "Aqueous polymeric coatings for pharmaceutical dosages forms" Ed. J.W. McGinity, Marcel Dekker, 1989, pp. 1-93]. Because of its excellent biocompatibility, poly(meth)acrylic acid and copolymers of (meth)acrylic acid are used for artificial implants, dental prosthesis, contact lenses, ointments and coatings for gastroresistant-enterosoluble formulations.

Examples of anionic poly(meth)acrylic acids include but are not limited to copolymers of methacrylic acid and ethyl acrylate - poly[(methacrylic acid)-co-(ethyl acrylate)], also

known as Eudragit. The chemical compositions of commercially available polymers (Eudragit L and S) are shown below.



The ratio of the free carboxyl groups to the ester groups is approximately 1:1 in Eudragit L and approximately 1:2 in Eudragit S. The mean molecular weight is calculated from viscosity measurement and equal to 135,000 Da. The polymers correspond to USP/NF, "Methacrylic Acid Copolymer, Type A" (Eudragit L) or "Type B" (Eudragit S). The copolymers are practically insoluble in water, but soluble in 1 N sodium hydroxide solution (upon neutralization of carboxyl groups) to give clear to slightly opalescent solutions.

B. Crosslinking the polymers with multivalent ions to form a hydrogel.

The water-soluble polymer with charged side groups is crosslinked by reacting the polymer with an aqueous solution containing multivalent ions of the opposite charge, either multivalent cations if the polymer has acidic side groups or multivalent anions if the polymer has basic side groups.

The term "pharmaceutically acceptable cation" refers to an organic or inorganic moiety that carries a positive charge that can be administered *in vivo* without undue toxicity to the host.

The term polyelectrolyte, as used herein, refers to a polymer with ionic side groups.

1. Cross-linking the polymers with acidic side groups by multivalent cations.

The preferred cations for cross-linking the polymers with acidic side groups to form a hydrogel are divalent and trivalent cations such as copper, calcium, aluminum, magnesium, strontium, barium, tin, chromium, and preferably zinc, although di-, tri- or tetra-functional organic cations such as salts of nitrogenous bases, for example, alkylammonium salts, such as piperidine dihydrochloride, the salt of ethylene diamine tetra(acetic acid), can also be used. Aqueous solutions of the salts of these cations are added to the polymers to form soft, highly swollen hydrogels and membranes. The higher the concentration of cation, or the higher the valence, the greater the degree of polymer cross-linking. Concentrations as low as 0.005 M have been demonstrated to crosslink the polymer. Higher concentrations are limited by the solubility of the salt.

2. Cross-linking the polymers with basic side groups with multivalent anions.

The preferred anions for cross-linking the polymers to form a hydrogel are divalent and trivalent anions such as low molecular weight dicarboxylic acids, for example, terephthalic acid, sulfate ions and carbonate ions. Aqueous solutions of the salts of these anions are added to the polymers to form soft, highly swollen hydrogels and membranes, as described with respect to cations.

C. Crosslinking the polymers with multivalent polyions to form a semi-permeable membrane.

In some embodiments, additional surface groups on the hydrogel polymer are reacted with polyions of opposite charge to form a semi-

permeable membrane on the surface of the hydrogel. The complexed polymer is stable and forms a semipermeable membrane on the microcapsules. The permeability of this membrane for a given entity
5 depends on the molecular weight of the polyion. When the hydrogel is in the form of a microcapsule (or microsphere), the core hydrogel can then be liquified by removing the multivalent ions, for example, by dialysis or addition of a chelating
10 agent.

1. Multivalent polycations useful for crosslinking.

A variety of polycations can be used to complex and thereby stabilize the polymer hydrogel
15 into a semi-permeable surface membrane. Examples of materials that can be used include polymers having basic reactive groups such as amine or imine groups, having a preferred molecular weight between 3,000 and 100,000, such as polyethylenimine and
20 polylysine, and proteins such albumin, gelatin, and lactoglobulin. These are commercially available. A preferred polycation is poly(L-lysine). Examples of synthetic polyamines include but are not limited to polyethyleneimine, poly(vinylamine), and
25 poly(allyl amine). There are also natural polycations, such as the polysaccharide chitosan, but these are not preferred.

2. Multivalent polyanions useful for crosslinking polymers with basic side groups.
30

Polyanions that can form a semi-permeable membrane by reacting with basic surface groups on the polymer hydrogel include polymers and
35 copolymers of acrylic acid, methacrylic acid, and other derivatives of acrylic acid, polymers with pendant SO_3H groups such as sulfonated polystyrene, and polystyrene with carboxylic acid groups.

D. Modification of Acidic Groups on the Polymer Backbone

1. Coupling of Molecules to modify the surface or to target the microparticle.

5

The ionically crosslinkable groups on the polymer can be modified by covalently coupling a poly(alkylene glycol) such as poly(ethylene glycol), proteins, peptides, oligosaccharides, carbohydrate, lipids, nucleotide sequences or other molecules to target the microparticles to specific regions of the body or to certain cell types, or minimize tissue adhesion or uptake by the reticuloendothelial system (RES). The targeting molecule can be, for example, a protein or peptide such as a hormone, antibody or antibody fragment such as the Fab or Fab₂ antibody fragments, or a specific cell surface receptor ligand that localizes at the target material.

10

15

20

2. Methods for coupling molecules to the microparticles.

25

The coupling involves forming ester, thioester, amide, or sulfamide linkages. Coupling hydroxy, thio, or amine groups with carboxy or sulfoxy groups is known to those skilled in the art.

30

35

The polymers can contain various functional groups, such as hydroxy, thio, and amine groups, that can react with a carboxylic acid or carboxylic acid derivative under the coupling conditions. Reactive functional groups not involved in the coupling chemistry must be protected to avoid unwanted side reactions. After the carboxylic acid or derivative reacts with a hydroxy, thio, or amine group to form an ester, thioester, or amide group, any protected functional groups can be deprotected by means known to those skilled in the art.

The term "protecting group" as used herein refers to a moiety which blocks a functional group

from reaction, and which is cleavable when there is no longer a need to protect the functional group. Suitable protecting groups for the hydroxyl group include, but are not limited to, certain ethers, esters and carbonates (Greene, T.W. and Wuts, P.G.M., "Protective groups in organic synthesis," John Wiley, New York, 2nd Ed. (1991)). Suitable protecting groups for the carboxyl group include, but are not limited to, those described in Green and Wuts, Protecting Groups in Organic Synthesis, John Wiley (1991). Side-chain functionalities such as carboxylic acids, alcohols, and amines may interfere with the coupling chemistry and must be appropriately protected.

As used herein, "side-chain functionality" refers to functional groups, such as hydroxy, thio, amine, keto, carboxy, alkenyl, alkynyl, carbonyl, and phosphorus derivatives such as phosphate, phosphonate and phosphinate in the polymer or material to be covalently attached to the polymer, that is not involved in coupling to form an ester, thioester, amide or sulfamide bond. Examples of suitable protecting groups are well known to those skilled in the art. See, generally, Greene and Wuts, Protecting Groups in Organic Chemistry, John Wiley (1991).

Examples of protecting groups for amine groups include, but are not limited to, t-butyloxycarbonyl (Boc), benzyloxycarbonyl (Cbz), o-nitrobenzyloxycarbonyl, and trifluoroacetamide (TFA).

3. Coupling other groups on the polymer with biological materials

Amine groups on a polymer backbone can be coupled with amine groups on a peptide by forming a Schiff base, using coupling agents such as glutaraldehyde. An example of this coupling is described by Allcock, et al., Macromolecules, Vol.

19(6), pp. 196 (1986), hereby incorporated by reference. In this example, trypsin was bound to amine groups on a polyphosphazene. An aminophenoxy polyphosphazene and trypsin were added to a buffer
5 solution. Glutaric dialdehyde was added to the solution, and the solution was kept at 0°C for 20 hours.

The amount of bound trypsin was determined by washing the excess trypsin from the polymer,
10 using Lowry protein measurement to determine the amount of unbound trypsin, and calculating the amount of bound trypsin by difference.

Amine groups can also be coupled with DCC or other dehydrating agents, as described above,
15 with carboxy groups on amino acids, proteins or peptides.

Alternatively, one can incorporate amino acids, proteins, or peptides into the polymer backbone by displacing chlorines on chlorine-
20 containing polyphosphazenes, such as polydichlorophosphazene. Since the carboxylate salt of carboxy groups can also displace the chlorine, the carboxy groups must be protected. Examples of this chemistry are described by Alcock, et al.,
25 Macromolecules, Vol. 10(4), pp. 824-831 (1977), hereby incorporated by reference.

Additionally, amine groups can be converted to diazonium salts, which can be reacted with amine or hydroxy groups on biological materials. An
30 example of this coupling is described by Allcock, et al., Macromolecules, Vol. 16(9), pp. 1405 (1983), hereby incorporated by reference.

For example, poly(15% 4-aminophenoxy/85% phenoxy) phosphazene is dissolved in THF containing
35 HCl, and the solution cooled to 0°C. A solution of NaNO₂ is added to form the diazonium salt. A buffered solution of d,l-epinephrine is added, and

the reaction proceeded in the dark, at 0°C, for 14 hours. A 60% yield is obtained.

Phenol or alcohol substituents on the polymer can be coupled with carboxylic or sulfonic acid groups on biological materials, such as a carboxy group on an amino acid, protein or peptide. The conditions for these coupling reactions are described above.

Aldehyde groups on polymers can be coupled with amines, as described above, by forming a schiff base. An example of this coupling is described by Allcock and Austin, Macromolecules, Vol. 14, pp. 1616 (1981), hereby incorporated by reference.

For example, Hexakis(4-aminophenoxy) cyclotriphosphazene (1 gram, 1.2 mmol) is dissolved in diethylene glycol (35 mL), and 16 mmol citral is added. The mixture is stirred at 25°C for 2 hours, HCl (18 mmol) is added, and the solution is warmed. Additional citral (15 mmol) is added. After 15 minutes at room temperature, 10 mL of water are added. After workup and recrystallization, the resulting yield is 88%.

II. Methods of Making Microparticles.

The method of preparing the microparticles should be selected to provide a microparticle having the desired size for the intended use. In a preferred embodiment for the preparation of injectable microparticles capable of passing through the pulmonary capillary bed, the microparticles should have a diameter of between approximately one and seven microns. Larger microparticles may clog the pulmonary bed, and smaller microparticles may not provide sufficient imaging capability. Larger microparticles may be useful for administration routes other than

injection, for example oral (for evaluation of the gastrointestinal tract) or by inhalation.

A. Preparation of a polymer solution.

In general, the polymer is dissolved or
5 dispersed into a solution which is then sprayed
into a solution of crosslinking counterions. This
is typically an aqueous solution or dispersion that
can include water-miscible organic solvents,
including but not limited to dialkyl sulfoxides,
10 such as dimethyl sulfoxide (DMSO); dialkyl
formamides, such as dimethyl formamide (DMF); C₁₋₅
alcohols, such as methanol and ethanol; ketones
such as acetone and methyl ethyl ketone; and ethers
such as tetrahydrofuran (THF), dibutyl ether and
15 diethyl ether. The solution can be neutral, acidic
or basic, and can contain salts or buffers. If the
ionic polymer is insoluble in water, or
insufficiently dispersible, the polymer can be
converted to its conjugate acid or base that is
20 typically more water soluble, and that conjugate
acid or base then exposed to the di- or multivalent
counterion for crosslinking.

B. Imaging Agents to be Encapsulated.

Gases to be encapsulated

25 The ratio of polymer to gas is determined
based on the gas that is to be encapsulated, for
example, as required to produce a particle size
small enough to be injected. Any desired inert gas
can be incorporated into the polymeric materials at
30 the time of hydrogel formation, including air,
argon, nitrogen, carbon dioxide, nitrogen dioxide,
methane, helium, neon, oxygen and perfluorocarbon.
Sterilized air or oxygen is a preferred imaging
contrast agent.

35 Imaging Agents

Other contrast agents can be incorporated
in place of the gas, or in combination with gas,

using the same methods. These are useful in imaging using the more common techniques such as ultrasound, magnetic resonance imaging (MRI), computer tomography (CT), x-ray, as well as the
5 less common positron emission tomography (PET) and single photon emission computerized tomography (PET).

Examples of suitable materials for ultrasound include the gases discussed above.

10 Examples of suitable materials for MRI include the gadolinium chelates currently available, such as diethylene triamine pentacetic acid (DTPA) and Gadopentotate dimeglumine, as well as iron, magnesium, manganese, copper and chromium.
15 These are typically administered in a dosage equivalent to 14 ml for a 70 kg person of a 0.5 M/liter solution.

Examples of materials useful for CT and x-rays include iodine based materials for intravenous
20 administration such as ionic monomers typified by Diatrizoate and iothalamate (administered at a dosage of 2.2 ml of a 30 mg/ml solution), non-ionic monomers typified by iopamidol, isohexol, and ioversol (administered at a dosage of 2.2 ml 150-
25 300 mg/ml), non-ionic dimers typified by iotrol and iodixanol, and ionic dimers, for example, ioxagalte. Other useful materials include barium for oral use.

30 **C. Atomization of polymer solution into a crosslinking solution.**

There are at least two methods for the preparation of injectable microparticles. In one method, a jet head is used that allows the co-extrusion of a solution of polymer and air to
35 produce nascent microencapsulated air bubbles which fall into a hardening solution of counterions. A second method employs ultrasound to introduce cavitation-induced bubbles into the polymer before

capsule formation by spraying. To incorporate gases other than air, a solution of the desired polymer is placed in an atmosphere of the desired gas and sonicated for a sufficient amount of time before crosslinking to ensure that gas bubbles are dispersed throughout the microparticulates. In either case, the determining factors on size of resulting microparticles will be the selection and concentration of polymer and solvent, and size of droplets formed by the atomizer.

1. Preparation of one to ten micron Microparticles

An example of an air-atomizing device is a Turbotak, from Turbotak, Inc., Waterloo, Ontario. A Turbotak is a hollow stainless steel cylinder, 2.64 cm. wide x 4 cm. long. Liquid is fed into the Turbotak from the top and pressurized air is fed from the side. The pressurized air mixes with the liquid, forcing tiny liquid droplets out through the orifice of the nozzle. The air pressure can be set to between 50 and 80 psig. The distance between the orifice of the Turbotak and the pan containing the crosslinking ions is fixed at between about one to two feet. The size of the nozzle orifice is 1 to 2 mm in diameter.

Air can be pressurized with a syringe pump such as a Razel pump, having a flow rate in the range of between 5 ml/hr and 30 ml/hr or a Sage pump, having a flow rate in the range of between 0.02 ml/min and 126 ml/min.

Mixing pressurized air with a polymer solution aerates the polymer solution and produces a high yield of air-encapsulated polymeric microparticles. Even without sonicating the polymer solution, microparticles produced using the Turbotak nozzle have entrapped air, as seen by light microscopy.

2. Method for the Preparation of larger Microparticles

Larger microparticles can be prepared using a droplet-forming apparatus by spraying an aqueous solution of polymer containing the agent of interest through an apparatus such as a plastic syringe, where the polymer solution is extruded through a needle located inside a tube through which air flows at a controlled rate.

The rate of polymer extrusion is controlled, for example, by a syringe pump. Droplets forming at the needle tip are forced off by the coaxial air stream and collected in the crosslinking solution, usually an aqueous solution of bi- or trivalent ions, where they cross-link and are hardened, for example, for between 15 and 30 minutes.

The shape and size of these microparticles depend on the polymer and cross-linker concentrations and parameters such as the polymer extrusion rate, air flow, and needle diameters used in the microencapsulation procedure.

A typical example for microparticle preparation utilizes PCPP polymer concentrations of between 1 and 5% (w/v), preferably around 2.5%, and calcium chloride concentrations of between 3 and 7.5% (w/v), preferably 7.5%, respectively. Polymer extrusion rates are between 50 and 100 mL/hour, preferably 70 mL/hour. Air flow rates are in the range of 5 L/hour. Needle diameters of between 18 and 26 gauge (G), preferably around 20 gauge, are used. Using the preferred conditions, the resultant microparticles are spherical with diameters in the range of 400-700 microns. In general, microparticles as small as 30 μ M can be prepared using this technique.

Macrospheres with millimeter diameters can be prepared by extruding the polymer through pasteur pipets or their equivalent.

5 D. Processing the polymeric
 microparticles to liquify the core.

 The polyionic-coated hydrogel microparticles are collected and further treated with buffer to remove the uncomplexed multivalent ions. For example, to remove uncomplexed
10 multivalent cations, microparticles can be treated with 0.9% (w/v) KCl with the pH adjusted to around 8.0. The KCl solution dissolves the internal gel, without affecting the external membrane. Other methods can also be used to liquefy the internal
15 gel, including using chelators such as EDTA and sodium citrate.

 III. Detecting contrast agent-encapsulating
 microparticles

 1. Detection of gas microbubbles

20 The relatively homogenous population of gel microparticles, filled with contrast agents, can be seen by an inverted microscope. Most microparticles produced by the first method are smaller than seven microns in diameter. Particle
25 size analysis can be performed on a Coulter counter.

 Due to their in vivo stability their potential application is extended beyond vascular imaging to liver and renal diseases, fallopian tube
30 diseases, detecting and characterizing tumor masses and tissues, and measuring peripheral blood velocity. The microparticles can optionally be linked with ligands that minimize tissue adhesion or that target the microparticles to specific
35 regions.

 The method for imaging by detection of gas bubbles in a patient uses a transducer which produces pulses, illustrative of ultrasonic

acoustic energy, having predetermined frequency characteristics. A first pulse has an increasing frequency with time, and a second pulse has a decreasing frequency with time. Imaging
5 arrangements produce images of the region within the specimen after exposure to the first and second pulses.

The conventional technique for determining the presence of bubbles in the blood stream uses a
10 Doppler shift in the frequency of the ultrasonic acoustic energy which is reflected by the blood. The amplitude of the Doppler bubble signal increases nearly proportionally with increases in the radius of the bubble. The human hearing
15 mechanism is considered the most accurate processor for recognizing whether bubble signals are present or absent. For this reason, it is preferable to have a skilled operator to obtain satisfactory results using Doppler blood flow monitoring
20 equipment.

To determine whether the air-filled microparticles are useful for *in vivo* imaging, the following *in vitro* method, described in more detail in the following examples, can be used.

25 Microparticles prepared by the above methods are suspended in a capped tissue culture tube. For ultrasound imaging, the tubes are placed on top of a pad covered with coupling medium above the transducer. The transducer is held in place at
30 roughly a 90° angle of incidence to minimize any motion artifacts. The transducer acts as a transmitter and also receives ultrasound radiation scattered back from the tube. B-mode and Doppler images are established for tubes filled with
35 polymeric microparticles and the resulting images are compared with a control consisting of an image from a tube containing buffer alone. The B-mode of

display gives a two dimensional image of a slice through the scanned tube.

This method was used to obtain in vitro results on the microparticles in the working examples described below. These results correlated well with the in vivo results, as shown by Doppler imaging techniques (described below). Since the in vitro and in vivo data showed a high degree of correlation in the working examples, this test is reasonably predictive of the in vivo stability of microparticles.

2. Detection of Other Contrast Agents

Other means of detection include PET (positron emission tomograph), (CAT) computer assisted tomography, x-rays, fluoroscopy, and MRI (magnetic resonance imaging). These are conducted using the standard techniques and equipment as used with other commercially available contrast agents.

The methods and compositions described above will be further understood with reference to the following non-limiting examples.

Example 1: Preparation of one to ten micron Eudragit S 100 Microparticles.

The microencapsulation procedure, optimized to produce microparticles in the size range of 1-10 μm , is as follows:

Preparation of Eudragit S 100 (5% w/v) solution.

1 gram of S 100 was dissolved overnight, at room temperature, with stirring in 1 N KOH, such that the carboxylic acid groups were neutralized. This required adding approximately 190 mg of KOH per gram of S 100. The solution was then diluted with double-distilled water to give a final polymer concentration of 5% (w/v) and solution pH around 7.0 (due to polymer neutralization). If the pH was greater than 7.0, the pH was adjusted with 1 N HCl.

Preparation of S 100 Microparticles

A solution of Eudragit S 100 (5% w/v) containing 0.2% Tween 20 was sonicated with a horn sonicator (output 8, for 15 minutes, in an ice-bath) to produce a gassed S 100 solution that was highly aerated and stable for hours. The gassed solution was extruded from a syringe pump (Razel Instrument) at 150 μ l min into an air-atomizing device (Turbotak, Turbotak, Inc., Waterloo, Ontario) and sprayed into a pan containing 250 mL of 15% calcium chloride solution with 0.5% Tween 20.

Upon contact with calcium chloride solution, S 100 was cross-linked by the divalent calcium ions to produce a relatively homogenous population of spherical gel microparticle, filled with air bubbles. The presence of air bubbles was shown by looking at the microparticle through an inverted microscope. Most S100 microparticles were smaller than 7 μ m. The yield of microparticle after one passage through a 7 μ m spectrum filter (polyester-based filter, Spectrum) was more than 90%. Particle size analysis (Coulter counter) gave the following number of particles: 90% of the particles were smaller than 5.448 μ m, 75% were smaller than 3.763 μ m, 50% were smaller than 2.692 μ m, 25% were smaller than 2.058 μ m, and 10% were smaller than 1.715 μ m. Analysis also indicated that 25% of total particle volume belonged to particles with diameter less than 7.65 μ m.

Example 2: Preparation of PCPP MicroparticlesPreparation of PCPP (2.5% w/v)

100 mg of PCPP were dissolved in 1 mL 30 mg/mL Na₂CO₃ (overnight, at room temperature, stirring) and then diluted with phosphate-buffered saline (PBS), pH 7.4 to give a final polymer concentration of 2.5% (w/v) and solution pH of 7.4

(due to polymer deprotonation), if not, the pH was adjusted with 1 N HCl.

Preparation of PCPP Microparticles.

A solution of PCPP (2.5% w/v) containing
5 0.2% Tween 20 was sonicated with a horn sonicator
(output 8, for 5 minutes, in an ice-bath) to
produce a gassed PCPP solution that was highly
aerated and stable for hours. The gassed solution
was extruded from a syringe pump (Razel Instrument)
10 at 150 μ l/min into an air-atomizing device
(Turbotak, Turbotak, Inc., Waterloo, Ontario) and
sprayed into a pan containing 250 mL of 7.5%
calcium chloride solution containing 0.5% Tween 20.
Upon contact with calcium chloride solution, PCPP
15 was crosslinked by the divalent calcium ions to
produce a relatively homogenous population of
spherical gel microparticle, filled with air
bubbles. The presence of air bubbles in the
microparticle was shown by looking at the
20 microparticle through an inverted microscope.
Particle size analysis (Coulter counter) gave the
following number of particles: 90% of the particles
were smaller than 14.77 μ m, 75% were smaller than
9.253 μ m, 50% were smaller than 5.84 μ m, 25% were
25 smaller than 4.166 μ m, and 10% were smaller than
3.372 μ m. Analysis also indicated that 10% of
total particle volume belonged to particles with
diameter less than 14.57 μ m.

30 **Example 3: Preparation of
Poly(methylmethacrylate)
Microparticles crosslinked with zinc.**

A solution of Eudragit™ S100 (5% w/v)
containing 0.25% Tween™ 20 is sonicated with a horn
sonicator (output 8, for 5 minutes, in an ice
35 bath), or with a vortex mixer (5 minutes) to
produce a gassed S100 solution that is highly
aerated and stable for hours. The gassed solution
is extruded from a syringe pump (Razel Instrument)

at 500 μ l/min into an air-atomizing device (Turbotak, Turbotak, Inc., Waterloo, Ontario) and sprayed into a pan containing 250 ml of 0.5% zinc chloride solution containing 0.5% Tween™ 20. The air pressure is set to 12 psi. The distance between the orifice of the Turbotak and the pan is fixed at 16 cm. Even without sonication of polymer solution, microparticulates produced by the Turbotak nozzle have entrapped air, as seen by light microscopy.

Upon contact with the zinc chloride solution, S100 is cross-linked by the divalent cations to produce a relatively homogeneous population of spherical microparticulates, filled with air bubbles, as seen with an inverted microscope. All S100 microparticulates were 4.5 microns in diameter, with nearly zero standard deviation, by light scattering.

Crosslinking with zinc is advantageous since it is expected that these ions will have less of a physiological effect than calcium. Moreover, the zinc ions produced an extremely narrow size distribution, with no sieving or filtration required, and the resulting microparticulates were highly echogenic.

Example 4: In vitro Ultrasound Imaging

Air-filled microparticles, at a concentration of 1×10^6 particles/mL, were suspended in a capped tissue culture tube with a length of 15 cm. and a depth of 1.5 cm. For ultrasound imaging, the tubes were placed on top of a pad containing a transducer, with coupling medium above the transducer. The transducer was held in place at a 90° angle of incidence to minimize any motion artifacts. B-mode and Doppler images were established for a tube filled with polymeric microparticles and the resulting images were

compared with a control consisting of an image from a tube that contained buffer alone.

A comparison was made between the B-mode sector images of tubes filled with saline and tubes
5 filled with S 100 microparticles (3-5 μm in diameter) and with PCPP microparticles (3-5 μm in diameter), respectively.

The brightness seen at the bottom of the picture of the tube filled with saline reflects the
10 saline/air interface within the tube. No echo was returned from the inside of the tube. In the tubes filled with both types of polymeric microparticles, a very strong echo was returned to the transducer, giving a clear image of the tube, and demonstrating
15 that the polymeric microparticles were highly echogenic. The polymeric microparticles were still highly echogenic, 24 hours and a week after preparation (during which they were kept at room temperature), as verified by subsequent B-mode
20 images.

Example 5: In vivo Ultrasound Imaging

In vivo imaging was performed with white rabbits weighing approximately 3.5 kg. The rabbits were anesthetized with 1 mL/kg Rabbit Mix (8:5:2
25 ratio of xylazine hydrochloride, 20 mg/mL; ketamine hydrochloride, 10 mg/mL; and acepromazine maleate, 100 mg/mL) administered intramuscularly.

Intravenous injections of saline or air-filled polymeric microparticles were performed
30 through the marginal ear vein using a 23-gauge butterfly catheter. Ultrasound imaging was performed with the Acuson scanner using a 7.5-MHz high-resolution linear transducer. Imaging of the aorta was performed before and after administering
35 the contrast agent. Both B-mode and Doppler images were established.

The color Doppler ultrasound is a particularly sensitive detector of bubbles. The effect of an ultrasonic contrast agent is readily identifiable by a sudden marked increase in the amplitude of the audible Doppler signal and easily recognized by all listeners. There is also a change in the quality of the Doppler sound, consisting primarily of an apparent increase in pitch.

To verify that the air bubbles remained encapsulated in the microparticle during *in vivo* application, a B-mode sector image of an aorta was taken after first injecting 5 mL saline, and then injecting 1 mL and then 2 mL of solutions containing PCPP polymeric microparticles (1×10^6 particles/mL) with a period of 5 minutes between each injection. No echoes were reflected from the aorta after the saline injection. However, immediately after injecting polymeric microparticles, the aorta was filled with echogenic microparticles. Injecting an additional 2 mL of microparticles resulted in a very strong echo, giving a clear image of the blood vessel and demonstrating that these microparticles were highly echogenic. The echo from the aorta lasted for more than 15 minutes, and it seemed that its intensity did not decline with time.

A color Doppler image of the aorta approximately 15 minutes after injection showed a significant increase in the image and the signal. Pictures were taken 15 and 20 minutes after injection, demonstrating that the PCPP microparticles are very stable *in vivo* (can survive the high pressure of the left chambers of the heart), can pass the capillary bed of the lung and are very echogenic.

We claim.

1. A microparticle formed of an ionically crosslinked biocompatible hydrogel comprising contrast agent encapsulated therein.

2. The microparticle of claim 1 wherein the diameter of the microparticle is between one and ten microns.

3. The microparticle of claim 1 wherein the hydrogel is prepared from an ionically crosslinkable synthetic polymer that is partially soluble in an aqueous solution prior to crosslinking and has charged side groups which are crosslinked by reacting the side groups with multivalent ions of the opposite charge.

4. The microparticle of claim 3 wherein the polymer is a polyelectrolyte selected from the group consisting of poly(phosphazenes), poly(acrylic acids), poly(methacrylic acids), copolymers of acrylic acid or methacrylic acid and polyvinyl ethers or poly(vinyl acetate), sulfonated polystyrene, poly(vinyl amines), poly(vinyl pyridine), poly(vinyl imidazole), imino substituted polyphosphazenes, and ammonium or quaternary salts thereof, and the polymer is soluble in an aqueous solution selected from the group consisting of water, aqueous alcohol, and buffered aqueous salt solutions.

5. The microparticles of claim 3 wherein the multivalent cation is selected from the group consisting of calcium, copper, aluminum, magnesium, strontium, barium, tin, chromium, zinc, organic cations, dicarboxylic acids, sulfate ions and carbonate ions.

6. The microparticles of claim 1 wherein the charged groups on the surface are further complexed with a multivalent polyion of the opposite charge to form a semi-permeable membrane.

7. The microparticles of claim 6 wherein the hydrogel is liquefied within the semi-permeable membrane by removing the multivalent ions.

8. The microparticles of claim 1 further comprising having coupled to the surface molecules decreasing attachment to tissue or uptake by the cells of the reticuloendothelial system.

9. The microparticles of claim 8 wherein the molecules are poly(alkylene glycol).

10. The microparticles of claim 1 further comprising having coupled to the surface molecules targeting the microparticles to specific cells.

11. The microparticles of claim 10 wherein the molecules are selected from the group consisting of proteins, peptides, oligosaccharides, nucleotide sequences, lipids and synthetic molecules having a specific affinity for a molecule characteristic of the targeted cells.

12. The microparticles of claim 1 wherein the contrast agents are selected from the group consisting of air, argon, nitrogen, carbon dioxide, nitrogen dioxide, methane, helium, neon, oxygen, perfluorocarbon, gadolinium chelates, iron, magnesium, manganese, copper, chromium, radiolabeled compounds and barium.

13. A method for preparing synthetic polymeric crosslinked microparticles encapsulating imaging contrast agents comprising the steps of:

a) entrapping contrast agent in an aqueous solution or dispersion of an ionically crosslinkable synthetic polymer that has charged side groups, and

b) reacting the polymer with a multivalent ion of the opposite charge to form a gel.

14. The method of claim 13 further comprising

c) complexing the charged groups on the surface of the gel with a multivalent polyion to form a semi-permeable membrane.

15. The method of claim 13 wherein the contrast agent is gas and the gas is entrapped in the polymer solution or dispersion by sonication of the polymer in the presence of the gas.

16. The method of claim 13 wherein the contrast agent is gas and the gas is mixed with the polymer solution or dispersion and atomized through an orifice forming droplets which are dispersed into the crosslinking solution.

17. The method of claim 14 wherein the polymer is a polyelectrolyte selected from the group consisting of polyphosphazenes, polyacrylic acids, polymethacrylic acids, copolymers of acrylic acid and polyvinyl acetate, polyvinyl ethers, polysulfonic acid derivatives, polystyrene sulfonates, poly(vinyl amines), poly(vinyl pyridine), poly(vinyl imidazole), imino substituted polyphosphazenes, and ammonium or quaternary salts thereof, and prior to crosslinking is soluble in an aqueous solution selected from the group consisting of water, aqueous alcohol, and buffered aqueous salt solutions.

18. The method of claim 13 wherein the multivalent cation is selected from the group consisting of calcium, copper, aluminum, magnesium, strontium, barium, tin, chromium, zinc, organic cations, dicarboxylic acids, sulfate ions and carbonate ions.

19. The method of claim 13 further comprising coupling to the surface of the microparticles molecules decreasing attachment to

tissue or uptake by the cells of the reticuloendothelial system.

20. The method of claim 13 further comprising coupling to the surface of the microparticles molecules targeting the microparticles to specific cells.

21. The method of claim 13 wherein the contrast agents are selected from the group consisting of air, argon, nitrogen, carbon dioxide, nitrogen dioxide, methane, helium, neon, oxygen, perfluorocarbon, gadolinium chelates, iron, magnesium, manganese, copper, chromium, radiolabeled compounds and barium.

22. A method for ultrasonic imaging for use in medical procedures, comprising the steps of:

a) injecting microparticles formed of an ionically crosslinked biocompatible hydrogel having a contrast agent encapsulated therein into a mammal; and

b) scanning a predetermined area to obtain an image of the area.

Internal. Application No
PCT/US 95/00519

According to International Patent Classification (IPC) or to both national classification and IPC

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,92 05778 (MASSACHUSETTS INST TECHNOLOGY ;PENNSYLVANIA RES CORP (US)) 16 April 1992 see page 3, paragraph 2 - paragraph 3 see claims 1-4,8-11,16,18,19,21,22; example 10	1
A	JP,A,60 034 731 (KOJIN KK) 22 February 1985	1-22
A,P	EP,A,0 627 632 (BRACCO INT BV) 7 December 1994 see claims	1-22

Y Patent family members are listed in annex.

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

*& document member of the same patent family

Date of mailing of the international search report

14.0695

Authorized officer _____

Berte, M.

INTERNATIONAL SEARCH REPORT

Internal . Application No

PCT/US 95/00519

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US AN=110:58221, ALLCOCK, HARRY R. ET AL 'An ionically crosslinkable polyphosphazene: poly[bis(carboxylatophenoxy)phosphazene] and its hydrogels*** and membranes' see abstract & MACROMOLECULES (1989), 22(1), 75-9 CODEN: MAMOBX;ISSN: 0024-9297, 1989</p>	1-22
X	<p>--- J. AM. CHEM. SOC. (1990), 112(21), 7832-3 CODEN: JACSAT;ISSN: 0002-7863, 1990 COHEN, SMADAR ET AL 'Ionically crosslinkable polyphosphazene: a novel polymer for microencapsulation' see the whole document</p>	1
X	<p>--- JOURNAL OF CONTROLLED RELEASE, vol. 27, October 1993 AMSTERDAM NL, pages 69-77, ALEXANDER K. ANDRIANOV ET AL. 'CONTROLLED RELEASE USING POLYPHOSPHAZENE HYDROGELS.' See abstract see page 71, column 1</p>	1-7,13, 14,17,22

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 95/00519

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: claim 22
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim 22 is directed to a method of treatment of (diagnostic method practised on) the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Internat. Application No

PCT/US 95/00519

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9205778	16-04-92	US-A-	5149543	22-09-92
		CA-A-	2093431	06-04-92
		EP-A-	0551411	21-07-93
		JP-T-	6505961	07-07-94
		US-A-	5308701	03-05-94

JP-A-60034731	22-02-85	NONE		

EP-A-0627632	07-12-94	EP-A-	0502814	09-09-92
		EP-A-	0638318	15-02-95
		JP-A-	5148161	15-06-93
		US-A-	5370901	06-12-94
